M5
Passive exercise for residents who cannot exercise conventionally.
Monthly Gross
Break-Even
Net — Trial Period
Net — Month 4+
Who They Are
Administrators, activities directors, and clinical directors at assisted living communities, skilled nursing facilities, and rehabilitation centers. Serving a population with high incidence of osteoporosis, poor circulation, chronic pain, and limited mobility — exactly the conditions the clinical research directly addresses. They need clinical credibility, resident safety evidence, and a clear ROI case for their board.
Pain Points
Residents with mobility limitations cannot access conventional exercise or most recovery modalities
Bone density loss, poor circulation, and muscle weakness are endemic in this population
Activities programming is expected to deliver genuine health benefit, not just scheduled engagement
Staff-to-resident ratios limit hands-on therapeutic work
Family members and regulators increasingly expect evidence-based wellness programming
The ROI Story
$999 for the 3-month trial. At $30/session — the accessible lower end of the pricing range — running 5 sessions/day, 5 days/week: break-even in 7 days. Monthly gross: $3,225. Net profit during trial: $2,892/month. From month 4 at $299/month: $2,926/month. For a facility already billing modality time, this is high-margin, staff-light revenue with a clinical research story that speaks directly to their population.
Key Messages for This Market
Lead with the bone loss efficacy research — greater than 80% is a statistic administrators hear and immediately understand
Blood flow normalization in 10 minutes is directly relevant to diabetic residents and those with peripheral vascular disease
Fully passive — no effort, no cardiovascular load, no fall risk during the session
Sessions require no specialized clinical staff in the room — a trained aide can assist residents in and out
At $30/session, sessions are affordable enough for families to subsidize as a regular benefit
$999 trial framing makes board approval straightforward — present it as a 90-day pilot, not a capital expenditure
Common Objections
Get Started